A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes

Virology Journal

Volumn 5, Issue , 2008, Pages

  Srinivasan, Alagarsamy ^a,b   Ayyavoo, Velpandi ^b   Mahalingam, Sundarasamy ^c   Kannan, Aarthi ^a,d   Boyd, Anne ^a   Datta, Debduti ^c   Kalyanaraman, Vaniambadi S ^e   Cristillo, Anthony ^e   Collman, Ronald G ^f   Morellet, Nelly ^g   Sawaya, Bassel E ^h   Murali, Ramachandran ^f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^d WELLESLEY COLLEGE   (United States)

^e ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g INSERM   (France)

^h TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; EPITOPE; VPR PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN DOMAIN; SEQUENCE ALIGNMENT; VIRUS REPLICATION; VIRUS TRANSMISSION; CHEMISTRY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR GENETICS; REGULATOR GENE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, VPR; GENES, VPR; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT; T-LYMPHOCYTES, CYTOTOXIC;

EID: 52649160233     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-99     Document Type: Article

References (106)

1. NK cell function in HIV-1 infection. G Alter M Altfeld, Curr Mol Med 2006 6 621 629 10.2174/156652406778195035 17022732
2. The role of CD8+ T-cell response in HIV infection. JM Benito M Lopez V Soriano, AIDS Rev 2004 6 79 88 15332430
3. T cell immunity to HIV: defining parameters of protection. HT Maecker VC Maino, Curr HIV Res 2003 1 249 259 10.2174/1570162033485294 15043207
4. Virus escape from CTL recognition. RA Koup, J Exp Med 1994 180 779 782 7520471 10.1084/jem.180.3.779
5. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. GS Ogg X Jin S Bonhoeffer PR Dunbar MA Nowak S Monard JP Segal Y Cao SL Rowland-Jones V Cerundolo, Science 1998 279 2103 2106 10.1126/science.279. 5359.2103 9516110
6. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. P Borrow H Lewicki BH Hahn GM Shaw MB Oldstone, J Virol 1994 68 6103 6110 8057491
7. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. T Matano M Kobayashi H Igarashi A Takeda H Nakamura M Kano C Sugimoto K Mori A Iida T Hirata, J Exp Med 2004 199 1709 1718 15210746 10.1084/jem.20040432
8. Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection. D O'Connor T Friedrich A Hughes TM Allen D Watkins, Immunol Rev 2001 183 115 126 10.1034/j.1600-065x.2001.1830110.x 11782252
9. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. TM Allen DH O'Connor P Jing JL Dzuris BR Mothe TU Vogel E Dunphy ME Liebl C Emerson N Wilson, Nature 2000 407 386 390 10.1038/35036559 11014195
10. HIV and SIV CTL escape: implications for vaccine design. PJ Goulder DI Watkins, Nat Rev Immunol 2004 4 630 640 10.1038/nri1417 15286729
11. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. W Fischer S Perkins J Theiler T Bhattacharya K Yusim R Funkhouser C Kuiken B Haynes NL Letvin BD Walker, Nat Med 2007 13 100 106 10.1038/nm1461 17187074
12. BTM Korber C Brander BF Hayens R Koup JP Moore BD Walker DI Watkins, HIV Molecular Immunology Los Alamos National Laboratory, Los Alamos, NM 2007
13. HIV-1 replication. EO Freed, Somat Cell Mol Genet 2001 26 13 33 10.1023/A:1021070512287 12465460
14. HIVs and their replication. EO Freed MA Martin, "Fields' Virology" Lippincott Williams & Wilkins, Philadelphia, Knipe DM, Howley PM, 2001 1971 2041
15. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. AM Sheehy NC Gaddis JD Choi MH Malim, Nature 2002 418 646 650 10.1038/nature00939 12167863
16. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. H Zhang B Yang RJ Pomerantz C Zhang SC Arunachalam L Gao, Nature 2003 424 94 98 12808465 10.1038/nature01707
17. HIV-1 Vpr: genetic diversity and functional features from the perspective of structure. PK Tungaturthi BE Sawaya V Ayyavoo R Murali A Srinivasan, DNA Cell Biol 2004 23 207 222 10.1089/104454904773819798 15142378
18. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. V Varthakavi RM Smith SP Bour K Strebel P Spearman, Proc Natl Acad Sci USA 2003 100 15154 15159 14657387 10.1073/pnas.2433165100
19. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. RL Willey F Maldarelli MA Martin K Strebel, J Virol 1992 66 7193 7200 1433512
20. Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. CO James MB Huang M Khan M Garcia-Barrio MD Powell VC Bond, J Virol 2004 78 3099 3109 14990729 10.1128/JVI.78.6.3099-3109.2004
21. Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein. ST Arold AS Baur, Trends Biochem Sci 2001 26 356 363 10.1016/S0968-0004(01)01846-1 11406408
22. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. R Geleziunas W Xu K Takeda H Ichijo WC Greene, Nature 2001 410 834 838 10.1038/35071111 11298454
23. HIV-1 Nef protein-induced apoptotic cytolysis of a broad spectrum of uninfected human blood cells independently of CD95(Fas). H Okada R Takei M Tashiro, FEBS Lett 1997 414 603 606 10.1016/S0014-5793(97)01080-6 9323045
24. Biology of the HIV Nef protein. SR Das S Jameel, Indian J Med Res 2005 121 315 332 15817946
25. Pathogenesis and medical aspects of HIV-1 infection. OJ Cohen AS Fauci, "Fields' Virology" Lippincott Williams & Wilkins, Philadelphia 2001 2043 2094
26. "HIV and the Pathogenesis of AIDS". JA Levy, ASM Press, Washington, DC 1998
27. Identification of HLA class I-associated amino acid polymorphisms in the HIV-1C proteome. CL Boutwell M Essex, AIDS Res Hum Retroviruses 2007 23 165 174 10.1089/aid.2006.0131 17263647
28. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. K Yusim C Kesmir B Gaschen MM Addo M Altfeld S Brunak A Chigaev V Detours BT Korber, J Virol 2002 76 8757 8768 12163596 10.1128/JVI.76.17.8757-8768.2002
29. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. CM Rousseau BA Birditt AR McKay JN Stoddard TC Lee S McLaughlin SW Moore N Shindo GH Learn BT Korber, J Virol Methods 2006 136 118 125 10.1016/j.jviromet.2006.04.009 16701907
30. HLA Class-I Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load. CM Rousseau MG Daniels JM Carlson C Kadie H Crawford A Prendergast P Matthews R Payne M Rolland DN Raugi, J Virol 2008 82 6434 46 18434400 10.1128/JVI.02455-07
31. Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells? AA Azad, Biochem Biophys Res Commun 2000 267 677 685 10.1006/bbrc.1999.1708 10673351
32. HIV-1, Vpr and the cell cycle. M Emerman, Curr Biol 1996 6 1096 1103 10.1016/S0960-9822(02)00676-0 8805364
33. Viral protein R of HIV-1. M Bukrinsky A Adzhubei, Rev Med Virol 1999 9 39 49 10.1002/(SICI)1099-1654(199901/03)9:1〈39::AID-RMV235〉3.0.CO;2-3 10371671
34. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. M Emerman MH Malim, Science 1998 280 1880 1884 10.1126/science.280. 5371.1880 9632380
35. Near full-length genome characterization of three additional HIV type 1 CRF13_cpx strains from Cameroon. KC Luk V Holzmayer J Yamaguchi P Swanson CA Brennan C Ngansop D Mbanya H Gayum MN Djuidje N Ndembi, AIDS Res Hum Retroviruses 2007 23 297 302 10.1089/aid.2006.0177 17331036
36. Genomic analysis of HIV type 1 strains derived from a mother and child pair of long-term nonprogressors. M Reinis B Weiser C Kuiken T Dong D Lang S Nachman Y Zhang S Rowland-Jones H Burger, AIDS Res Hum Retroviruses 2007 23 309 315 10.1089/aid.2006.0180 17331038
37. Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu. CM Bell BJ Connell A Capovilla WD Venter WS Stevens MA Papathanasopoulos, AIDS Res Hum Retroviruses 2007 23 322 330 10.1089/aid.2006.0181 17331040
38. Molecular Characterization of the HIV Type 1 vpr Gene in Infected Chinese Former Blood/Plasma Donors at Different Stages of Diseases. C Shen P Gupta H Wu X Chen X Huang Y Zhou Y Chen, AIDS Res Hum Retroviruses 2008 24 661 666 10.1089/aid.2007.0270 18366311
39. Consistent risk group-associated differences in human immunodeficiency virus type 1 vpr, vpu and V3 sequences despite independent evolution. CL Kuiken MT Cornelissen F Zorgdrager S Hartman AJ Gibbs J Goudsmit, J Gen Virol 1996 77 Pt 4 783 792 10.1099/0022-1317-77-4-783 8627267
40. NMR structure of the HIV-1 regulatory protein VPR. N Morellet S Bouaziz P Petitjean BP Roques, J Mol Biol 2003 327 215 227 10.1016/S0022-2836(03)00060-3 12614620
41. Evidence for a cytopathogenicity determinant in HIV-1 Vpr. M Somasundaran M Sharkey B Brichacek K Luzuriaga M Emerman JL Sullivan M Stevenson, Proc Natl Acad Sci USA 2002 99 9503 9508 12093916 10.1073/pnas.142313699
42. Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo. J Votteler N Studtrucker S Sorgel J Munch E Rucker F Kirchhoff B Schick P Henklein T Fossen K Bruns, J Virol 2007 81 9572 9576 17553868 10.1128/JVI.02803-06
43. Nuclear localization of Vpr is crucial for the efficient replication of HIV-1 in primary CD4+ T cells. S Iijima Y Nitahara-Kasahara K Kimata W Zhong Zhuang M Kamata M Isogai M Miwa Y Tsunetsugu-Yokota Y Aida, Virology 2004 327 249 261 10.1016/j.virol.2004.06.024 15351213
44. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. P Di Marzio S Choe M Ebright R Knoblauch NR Landau, J Virol 1995 69 7909 7916 7494303
45. Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation. S Mahalingam SA Khan MA Jabbar CE Monken RG Collman A Srinivasan, Virology 1995 207 297 302 10.1006/viro.1995.1081 7871742
46. Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. S Mahalingam SA Khan R Murali MA Jabbar CE Monken RG Collman A Srinivasan, Proc Natl Acad Sci USA 1995 92 3794 3798 7731985 10.1073/pnas.92.9.3794
47. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. W Paxton RI Connor NR Landau, J Virol 1993 67 7229 7237 8230445
48. The first HxRxG motif in simian immunodeficiency virus mac239 Vpr is crucial for G(2)/M cell cycle arrest. SM Mueller SM Lang, J Virol 2002 76 11704 11709 12388729 10.1128/JVI.76.22.11704-11709.2002
49. Functional conservation of HIV-1 Vpr and variability in a mother-child pair of long-term non-progressors. Y Zhao M Chen B Wang J Yang RT Elder XQ Song M Yu NK Saksena, Virus Res 2002 89 103 121 10.1016/S0168-1702(02)00127-2 12367754
50. Structure-functional analysis of human immunodeficiency virus type 1 (HIV-1) Vpr: role of leucine residues on Vpr-mediated transactivation and virus replication. D Thotala EA Schafer PK Tungaturthi B Majumder ML Janket M Wagner A Srinivasan S Watkins V Ayyavoo, Virology 2004 328 89 100 10.1016/j.virol.2004. 07.013 15380361
51. Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. G Jacquot E Le Rouzic A David J Mazzolini J Bouchet S Bouaziz F Niedergang G Pancino S Benichou, Retrovirology 2007 4 84 18039376 10.1186/1742-4690-4-84
52. Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved. J Forget XJ Yao J Mercier EA Cohen, J Mol Biol 1998 284 915 923 10.1006/jmbi.1998.2206 9837715
53. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. XJ Yao RA Subbramanian N Rougeau F Boisvert D Bergeron EA Cohen, J Virol 1995 69 7032 7044 7474123
54. Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast. M Chen RT Elder M Yu MG O'Gorman L Selig R Benarous A Yamamoto Y Zhao, J Virol 1999 73 3236 3245 10074177
55. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. MA Vodicka DM Koepp PA Silver M Emerman, Genes Dev 1998 12 175 185 9436978 10.1101/gad.12.2.175
56. Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. SP Singh B Tomkowicz D Lai M Cartas S Mahalingam VS Kalyanaraman R Murali A Srinivasan, J Virol 2000 74 10650 10657 11044109 10.1128/JVI.74.22.10650-10657.2000
57. Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms. M Kamata Y Aida, J Virol 2000 74 7179 7186 10888660 10.1128/JVI.74.15.7179-7186.2000
58. Vpr cytopathicity independent of G2/M cell cycle arrest in human immunodeficiency virus type 1-infected CD4+ T cells. DL Bolton MJ Lenardo, J Virol 2007 81 8878 8890 17553871 10.1128/JVI.00122-07
59. Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages. MP Sherman CM de Noronha LA Eckstein J Hataye P Mundt SA Williams JA Neidleman MA Goldsmith WC Greene, J Virol 2003 77 7582 7589 12805458 10.1128/JVI.77.13.7582-7589.2003
60. Nuclear import, virion incorporation, and cell cycle arrest/ differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. S Mahalingam V Ayyavoo M Patel T Kieber-Emmons DB Weiner, J Virol 1997 71 6339 6347 9261351
61. DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. L Tan E Ehrlich XF Yu, J Virol 2007 81 10822 10830 17626091 10.1128/JVI.01380-07
62. Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. K Hrecka M Gierszewska S Srivastava L Kozaczkiewicz SK Swanson L Florens MP Washburn J Skowronski, Proc Natl Acad Sci USA 2007 104 11778 11783 17609381 10.1073/pnas.0702102104
63. Transcription factor TFIIH components enhance the GR coactivator activity but not the cell cycle-arresting activity of the human immunodeficiency virus type-1 protein Vpr. T Kino M Tsukamoto G Chrousos, Biochem Biophys Res Commun 2002 298 17 23 10.1016/S0006-291X(02)02442-7 12379213
64. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. MP Sherman CM de Noronha D Pearce WC Greene, J Virol 2000 74 8159 8165 10933727 10.1128/JVI.74.17.8159-8165.2000
65. A novel inducible expression system to study transdominant mutants of HIV-1 Vpr. Y Zhou L Ratner, Virology 2001 287 133 142 10.1006/viro.2001.1031 11504548
66. Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. H Kitayama Y Miura Y Ando S Hoshino Y Ishizaka Y Koyanagi, J Virol 2008 82 2528 2542 18094160 10.1128/JVI.02094-07
67. Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest. Y Zhou Y Lu L Ratner, Virology 1998 242 414 424 10.1006/viro.1998.9028 9514978
68. Phosphorylation of Vpr regulates HIV type 1 nuclear import and macrophage infection. I Agostini S Popov T Hao JH Li L Dubrovsky O Chaika N Chaika R Lewis M Bukrinsky, AIDS Res Hum Retroviruses 2002 18 283 288 10.1089/ 088922202753472856 11860675
69. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. DH Barouch J Kunstman J Glowczwskie KJ Kunstman MA Egan FW Peyerl S Santra MJ Kuroda JE Schmitz K Beaudry, J Virol 2003 77 7367 7375 12805435 10.1128/JVI.77.13.7367-7375.2003
70. Immunological and pharmacological approaches to the control of retroviral infections. EA Emini HY Fan, "Retroviruses" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Coffin JM, Hughes SH, Varmus HE, 1997 637 706
71. Antibody-based HIV-1 vaccines: recent developments and future directions. D Montefiori Q Sattentau J Flores J Esparza J Mascola, PLoS Med 2007 4 e348 18052607 10.1371/journal.pmed.0040348
72. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. M Altfeld TM Allen, Trends Immunol 2006 27 504 510 10.1016/j.it.2006.09. 007 16997629
73. HIV vaccine design and the neutralizing antibody problem. DR Burton RC Desrosiers RW Doms WC Koff PD Kwong JP Moore GJ Nabel J Sodroski IA Wilson RT Wyatt, Nat Immunol 2004 5 233 236 10.1038/ni0304-233 14985706
74. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. X Jin DE Bauer SE Tuttleton S Lewin A Gettie J Blanchard CE Irwin JT Safrit J Mittler L Weinberger, J Exp Med 1999 189 991 998 10075982 10.1084/jem.189.6.991
75. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. JE Schmitz MJ Kuroda S Santra VG Sasseville MA Simon MA Lifton P Racz K Tenner-Racz M Dalesandro BJ Scallon, Science 1999 283 857 860 10.1126/science.283.5403.857 9933172
76. HIV-1 sequence variation: drift, shift, and attenuation. MH Malim M Emerman, Cell 2001 104 469 472 10.1016/S0092-8674(01)00234-3 11239404
77. Selection forces and constraints on retroviral sequence variation. J Overbaugh CR Bangham, Science 2001 292 1106 1109 10.1126/science.1059128 11352065
78. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. T Bhattacharya M Daniels D Heckerman B Foley N Frahm C Kadie J Carlson K Yusim B McMahon B Gaschen, Science 2007 315 1583 1586 10.1126/science.1131528 17363674
79. AIDS vaccines: on the trail of two trials. JP Moore, Nature 2002 415 365 366 10.1038/415365a 11807523
80. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. ZL Brumme CJ Brumme D Heckerman BT Korber M Daniels J Carlson C Kadie T Bhattacharya C Chui J Szinger, PLoS Pathog 2007 3 e94 17616974 10.1371/journal.ppat.0030094
81. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. H Crawford JG Prado A Leslie S Hue I Honeyborne S Reddy M van der Stok Z Mncube C Brander C Rousseau, J Virol 2007 81 8346 8351 17507468 10.1128/JVI.00465-07
82. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. OO Yang PT Sarkis A Ali JD Harlow C Brander SA Kalams BD Walker, J Exp Med 2003 197 1365 1375 12743169 10.1084/jem.20022138
83. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. FW Peyerl HS Bazick MH Newberg DH Barouch J Sodroski NL Letvin, J Virol 2004 78 13901 13910 15564498 10.1128/JVI.78.24. 13901-13910.2004
84. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. A Leslie D Kavanagh I Honeyborne K Pfafferott C Edwards T Pillay L Hilton C Thobakgale D Ramduth R Draenert, J Exp Med 2005 201 891 902 15781581 10.1084/jem.20041455
85. Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. TC Friedrich CA Frye LJ Yant DH O'Connor NA Kriewaldt M Benson L Vojnov EJ Dodds C Cullen R Rudersdorf, J Virol 2004 78 2581 2585 14963161 10.1128/JVI.78.5.2581-2585.2004
86. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design. M Altfeld TM Allen ET Kalife N Frahm MM Addo BR Mothe A Rathod LL Reyor J Harlow XG Yu, J Virol 2005 79 5000 5005 15795285 10.1128/JVI.79.8.5000-5005. 2005
87. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. P Kiepiela K Ngumbela C Thobakgale D Ramduth I Honeyborne E Moodley S Reddy C de Pierres Z Mncube N Mkhwanazi, Nat Med 2007 13 46 53 10.1038/nm1520 17173051
88. Vpr is preferentially targeted by CTL during HIV-1 infection. M Altfeld MM Addo RL Eldridge XG Yu S Thomas A Khatri D Strick MN Phillips GB Cohen SA Islam, J Immunol 2001 167 2743 2752 11509618
89. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. MM Addo XG Yu ES Rosenberg BD Walker M Altfeld, DNA Cell Biol 2002 21 671 678 10.1089/104454902760330219 12396610
90. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. MM Addo XG Yu A Rathod D Cohen RL Eldridge D Strick MN Johnston C Corcoran AG Wurcel CA Fitzpatrick, J Virol 2003 77 2081 2092 12525643 10.1128/JVI.77.3.2081- 2092.2003
91. Identification of HIV-1 specific T lymphocyte responses in highly exposed persistently seronegative Chinese. HW Liu KX Hong J Ma L Yuan S Liu JP Chen YZ Zhang YH Ruan JQ Xu YM Shao, Chin Med J (Engl) 2006 119 1616 1621 17042974
92. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Cao J McNevin S Holte L Fink L Corey MJ McElrath, J Virol 2003 77 6867 6878 12768006 10.1128/JVI.77.12.6867-6878.2003
93. Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. M Lichterfeld XG Yu S Le Gall M Altfeld, Trends Immunol 2005 26 166 171 10.1016/j.it.2005.01.003 15745859
94. Identification of HIV-derived HLA class I restricted CTL epitope: Insights into TCR repertoire, CTL escape and viral fitness. N Frahm C Linde C Brander, "HIV Molecular Immunology 2006" Los Alamos National Laboratory, Theoritical Biology and Biophysics, Los Alamos, New Mexico 2007 3
95. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. ME Feeney Y Tang K Pfafferott KA Roosevelt R Draenert A Trocha XG Yu C Verrill T Allen C Moore, J Immunol 2005 174 7524 7530 15944251
96. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. V Novitsky H Cao N Rybak P Gilbert MF McLane S Gaolekwe T Peter I Thior T Ndung'u R Marlink, J Virol 2002 76 10155 10168 12239290 10.1128/JVI.76.20.10155-10168.2002
97. Extensive HLA class I allele promiscuity among viral CTL epitopes. N Frahm K Yusim TJ Suscovich S Adams J Sidney P Hraber HS Hewitt CH Linde DG Kavanagh T Woodberry, Eur J Immunol 2007 37 2419 2433 10.1002/eji.200737365 17705138
98. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. MA Altfeld B Livingston N Reshamwala PT Nguyen MM Addo A Shea M Newman J Fikes J Sidney P Wentworth, J Virol 2001 75 1301 1311 11152503 10.1128/JVI.75.3.1301-1311.2001
99. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. S Corbet HV Nielsen L Vinner S Lauemoller D Therrien S Tang G Kronborg L Mathiesen P Chaplin S Brunak, J Gen Virol 2003 84 2409 2421 10.1099/vir.0.19152-0 12917462
100. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. XG Yu MM Addo ES Rosenberg WR Rodriguez PK Lee CA Fitzpatrick MN Johnston D Strick PJ Goulder BD Walker M Altfeld, J Virol 2002 76 8690 8701 12163589 10.1128/JVI.76.17.8690-8701.2002
101. Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. F Bernardin D Kong L Peddada LA Baxter-Lowe E Delwart, J Virol 2005 79 11523 11528 16103205 10.1128/JVI.79.17.11523-11528.2005
102. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. P Kiepiela AJ Leslie I Honeyborne D Ramduth C Thobakgale S Chetty P Rathnavalu C Moore KJ Pfafferott L Hilton, Nature 2004 432 769 775 10.1038/nature03113 15592417
103. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. TM Allen XG Yu ET Kalife LL Reyor M Lichterfeld M John M Cheng RL Allgaier S Mui N Frahm, J Virol 2005 79 12952 12960 16188997 10.1128/JVI.79.20.12952-12960.2005
104. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. F Liu PL Bergami M Duval D Kuhrt M Posner L Cavacini, AIDS Res Hum Retroviruses 2003 19 597 607 10.1089/088922203322230969 12908937
105. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. A Propato E Schiaffella E Vicenzi V Francavilla L Baloni M Paroli L Finocchi N Tanigaki S Ghezzi R Ferrara, Hum Immunol 2001 62 561 576 10.1016/S0198-8859(01) 00245-2 11390031
106. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. PJ Goulder MM Addo MA Altfeld ES Rosenberg Y Tang U Govender N Mngqundaniso K Annamalai TU Vogel M Hammond, J Virol 2001 75 1339 1347 11152507 10.1128/JVI.75.3.1339-1347.2001